{"id":478080,"date":"2021-04-19T09:03:33","date_gmt":"2021-04-19T13:03:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/"},"modified":"2021-04-19T09:03:33","modified_gmt":"2021-04-19T13:03:33","slug":"mymd-pharmaceuticals-begins-trading-on-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/","title":{"rendered":"MyMD Pharmaceuticals Begins Trading on Nasdaq"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>MyMD Pharmaceuticals Begins Trading on Nasdaq<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Phase II Trial results expected by year end<\/i><\/li>\n<\/ul>\n<p>BALTIMORE&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nMyMD Pharmaceuticals, Inc. (\u201cMYMD\u201d) is pleased to announce that its common shares will begin trading today, April 19<sup>th<\/sup>, on the NASDAQ Stock Market (\u201cNASDAQ\u201d) under the ticker symbol \u201cMYMD.\u201d\n<\/p>\n<p>\nMyMD Pharmaceuticals intends to focus on developing and commercializing novel immunotherapy pipeline assets, including <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.mymd.com%2Fpipeline%2Fmymd-1&amp;esheet=52413799&amp;newsitemid=20210419005502&amp;lan=en-US&amp;anchor=MYMD-1&amp;index=1&amp;md5=cf70b85e147b689bb143dc9d13564797\">MYMD-1<\/a>, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MyMD recently announced a Phase II trial that will initiate during the near term with results expected by year end.\n<\/p>\n<p>\n&#8220;The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and our clinical development pipeline, all of which should lead to increased visibility in the near term for our investors,\u201d said Chris Chapman, M.D., President and Chief Medical Officer of MyMD.\n<\/p>\n<p><b>About MyMD Pharmaceuticals, Inc.<\/b><\/p>\n<p>\nMyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\u03b1 and other pro-inflammatory cytokines. MYMD-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective TNF-\u03b1 blocking drugs, and aging and longevity. SUPERA-CBD is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (CBD) that targets numerous key receptors including CB2 and opioid receptors and inhibits monoamine oxidase. SUPERA-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mymd.com&amp;esheet=52413799&amp;newsitemid=20210419005502&amp;lan=en-US&amp;anchor=www.mymd.com&amp;index=2&amp;md5=7c7f771484ff3b69de5c09efceae536e\">www.mymd.com<\/a>.\n<\/p>\n<p><b>Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MYMD nor its affiliates assume any duty to update forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MYMD\u2019s ability to, obtain and maintain regulatory approvals for clinical trials of MYMD\u2019s pharmaceutical candidates, the timing and results of MMMD\u2019s planned clinical trials for its pharmaceutical candidates, the amount of funds MYMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MYMD operates; MYMD\u2019s ability to retain and attract senior management and other key employees; MYMD\u2019s ability to quickly and effectively respond to new technological developments; MYMD\u2019s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MYMD\u2019s proprietary rights; and the impact of the ongoing COVID-19 pandemic on MYMD\u2019s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MYMD is set forth in the registration statement on Form S-4 filed by MYMD on January 15, 2021, as amended. Forward-looking statements speak only as of the date they are made and MYMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210419005502\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210419005502\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Brett Mass<br \/>\n<br \/>646-536-7331<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:brett@haydenir.com\">brett@haydenir.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.haydenir.com&amp;esheet=52413799&amp;newsitemid=20210419005502&amp;lan=en-US&amp;anchor=www.haydenir.com&amp;index=3&amp;md5=27651b8320e87acfd21c162823ec9f55\">www.haydenir.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Will Johnson<br \/>\n<br \/>201-465-8019<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3Dn__6lETlUgMx6ucVawlUqKmcSUHLdDhFYiDBZJZB-LuSXP1mIOPql1uxg4Y_ZW7u6NZbVKvV4dW1Y1-3PI9b885_FO9DLfVw6VjimmCN6LLakrPC2IlyKOvFvbcCcMYi&amp;esheet=52413799&amp;newsitemid=20210419005502&amp;lan=en-US&amp;anchor=MYMD%40antennagroup.com&amp;index=4&amp;md5=b9d21770c403c01f3a3924169c225790\">MYMD@antennagroup.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.antennagroup.com&amp;esheet=52413799&amp;newsitemid=20210419005502&amp;lan=en-US&amp;anchor=www.antennagroup.com&amp;index=5&amp;md5=900336397d3aab1ecf835d72c49120f5\">www.antennagroup.com <\/a><\/p>\n<p><b>KEYWORDS:<\/b> Maryland United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>MyMD Pharmaceuticals Begins Trading on Nasdaq Phase II Trial results expected by year end BALTIMORE&#8211;(BUSINESS WIRE)&#8211; MyMD Pharmaceuticals, Inc. (\u201cMYMD\u201d) is pleased to announce that its common shares will begin trading today, April 19th, on the NASDAQ Stock Market (\u201cNASDAQ\u201d) under the ticker symbol \u201cMYMD.\u201d MyMD Pharmaceuticals intends to focus on developing and commercializing novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MyMD recently announced a Phase II trial that will initiate during the near term with results expected by year end. &#8220;The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MyMD Pharmaceuticals Begins Trading on Nasdaq&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-478080","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MyMD Pharmaceuticals Begins Trading on Nasdaq Phase II Trial results expected by year end BALTIMORE&#8211;(BUSINESS WIRE)&#8211; MyMD Pharmaceuticals, Inc. (\u201cMYMD\u201d) is pleased to announce that its common shares will begin trading today, April 19th, on the NASDAQ Stock Market (\u201cNASDAQ\u201d) under the ticker symbol \u201cMYMD.\u201d MyMD Pharmaceuticals intends to focus on developing and commercializing novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MyMD recently announced a Phase II trial that will initiate during the near term with results expected by year end. &#8220;The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and &hellip; Continue reading &quot;MyMD Pharmaceuticals Begins Trading on Nasdaq&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T13:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MyMD Pharmaceuticals Begins Trading on Nasdaq\",\"datePublished\":\"2021-04-19T13:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/\"},\"wordCount\":655,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/\",\"name\":\"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-19T13:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mymd-pharmaceuticals-begins-trading-on-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MyMD Pharmaceuticals Begins Trading on Nasdaq\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk","og_description":"MyMD Pharmaceuticals Begins Trading on Nasdaq Phase II Trial results expected by year end BALTIMORE&#8211;(BUSINESS WIRE)&#8211; MyMD Pharmaceuticals, Inc. (\u201cMYMD\u201d) is pleased to announce that its common shares will begin trading today, April 19th, on the NASDAQ Stock Market (\u201cNASDAQ\u201d) under the ticker symbol \u201cMYMD.\u201d MyMD Pharmaceuticals intends to focus on developing and commercializing novel immunotherapy pipeline assets, including MYMD-1, a first-in-class drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan. MyMD recently announced a Phase II trial that will initiate during the near term with results expected by year end. &#8220;The listing of our shares on the Nasdaq marks a significant milestone for the company, in combination with our upcoming phase II trial and &hellip; Continue reading \"MyMD Pharmaceuticals Begins Trading on Nasdaq\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T13:03:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MyMD Pharmaceuticals Begins Trading on Nasdaq","datePublished":"2021-04-19T13:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/"},"wordCount":655,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/","name":"MyMD Pharmaceuticals Begins Trading on Nasdaq - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-19T13:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210419005502r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mymd-pharmaceuticals-begins-trading-on-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MyMD Pharmaceuticals Begins Trading on Nasdaq"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=478080"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478080\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=478080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=478080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=478080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}